| |

Step Counts for Cancer Prognosis: Could it Work for Mesothelioma?

steps counts for cancer prognosis

Cancer researchers in New York are exploring the concept of using step counts for cancer prognosis. If further studies back it up, the technique might help predict outcomes for people with mesothelioma.

The new study involved people with non-small cell lung cancer. The patients wore commercial fitness trackers so doctors could see how much they walked. 

The researchers compared step levels with treatment outcomes. They concluded that there is value to using step counts for cancer prognosis. It may even be more effective than some more traditional methods for predicting survival.

Cancer Prognosis and Chemoradiotherapy

Mesothelioma survival usually depends on how well patients respond to standard treatments. Healthier, more active cancer patients tend to have better outcomes. 

Chemotherapy and radiation are common pleural mesothelioma treatments. These are powerful therapies with significant effects on the body. In some cases, chemotherapy and/or radiotherapy can make mesothelioma patients sicker. 

Doctors may run tests to determine if a mesothelioma patient is fit for a particular type of treatment. 

But the New York study suggests that step counts for cancer prognosis may help doctors make that call. Step counts have the added benefits of being inexpensive and non-invasive.

Measuring Step Counts for Cancer Prognosis

To determine how to use step counts for cancer prognosis, researchers gave commercial fitness trackers to 50 lung cancer patients. The patients were part of a clinical trial for advanced non-small cell lung cancer. 

During the clinical trial, patients underwent concurrent chemotherapy and radiotherapy. They wore the fitness trackers from enrollment until the end of their first week of radiotherapy. 

Researchers classified patients into three categories based on how much they walked. Nine patients (18%) were designated “highly active”. Twenty-three patients (46%) were “moderately active”. The remaining 18 subjects (36%) were inactive. 

“Inactive subjects were more likely to be hospitalized during the radiotherapy course than other subjects (50% v. 9%, p=0.004) and less likely to complete radiotherapy without delay,” reports lead study author Nitin Ohri, MD. 

Do Higher Step Counts Keep Cancer at Bay?

Using step counts for cancer prognosis may help predict tumor growth, too. It took just 5.3 months for lung tumors to start growing again in the inactive study subjects. But the lung cancer patients who were moderately or highly active lived without cancer progression for a median of 18.3 months. 

The more active cancer patients survived longer, too. Most of the inactive group had died by 15 months after treatment. But the other patients were still alive when the study ended. 

Performance status (PS) is a score doctors often use to describe how well a mesothelioma patient is functioning overall. But the New York researchers found that PS was not as helpful as step counts for lung cancer prognosis.

The current study focused only on lung cancer. But previous studies have shows a connection between exercise and mesothelioma outcomes.

A study in the European Journal of Clinical Nutrition earlier this year year showed mesothelioma patients with higher muscle mass had a better quality of life. And a 2018 Australian study suggests that mesothelioma patients should aim for at least two-and-a-half hours of moderate intensity aerobic exercise each week.

Source:

Ohri, N, et al, “Daily step counts: A new prognostic factor in locally advanced non-small cell lung cancer?”, August 7, 2019, International Journal of Radiation Oncology, https://doi.org/10.1016/j.ijrobp.2019.07.055

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…